Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

10x Genomics (TXG) Invested Capital (2018 - 2025)

Historic Invested Capital for 10x Genomics (TXG) over the last 8 years, with Q4 2025 value amounting to $796.3 million.

  • 10x Genomics' Invested Capital rose 1213.74% to $796.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $796.3 million, marking a year-over-year increase of 1213.74%. This contributed to the annual value of $796.3 million for FY2025, which is 1213.74% up from last year.
  • As of Q4 2025, 10x Genomics' Invested Capital stood at $796.3 million, which was up 1213.74% from $785.1 million recorded in Q3 2025.
  • 10x Genomics' Invested Capital's 5-year high stood at $817.6 million during Q4 2021, with a 5-year trough of $706.9 million in Q1 2025.
  • For the 5-year period, 10x Genomics' Invested Capital averaged around $767.3 million, with its median value being $779.7 million (2022).
  • In the last 5 years, 10x Genomics' Invested Capital soared by 10052.34% in 2021 and then plummeted by 1041.28% in 2024.
  • Quarter analysis of 5 years shows 10x Genomics' Invested Capital stood at $817.6 million in 2021, then fell by 1.45% to $805.7 million in 2022, then fell by 8.03% to $741.0 million in 2023, then fell by 4.17% to $710.1 million in 2024, then increased by 12.14% to $796.3 million in 2025.
  • Its Invested Capital stands at $796.3 million for Q4 2025, versus $785.1 million for Q3 2025 and $773.3 million for Q2 2025.